Search
-
News
The lack of participation in clinical research may be the Achilles heel facing today’s cancer community. According to a new survey of more than 1,500 consumers and nearly 600 physicians conducted on behalf of MSK, only 35 percent of Americans indicated that they were “likely” to enroll in a clinical trial. For more information or to schedule an interview, please contact [email protected].
… Monday, May 23, 2016 The lack of participation in clinical research may be the Achilles heel facing today’s cancer community. According to a new survey of more than 1,500 consumers and nearly 600 physicians conducted on behalf of MSK, only 35 percent of Americans indicated that they were “likely” to
-
News
New MSK research helped develop a machine-learning tool to help find cancer cells that remain after surgery; led to FDA approval for CAR T cell therapy against mantle cell lymphoma; tested a liquid biopsy approach that shows promise in detecting lung cancer; found checkpoint inhibitors were effective against endometrial and ovarian cancers with DNA-repair deficiency; and shed new light on mTOR's role in metabolic enzyme degradation.
… Tuesday, June 25, 2024 New research from Memorial Sloan Kettering Cancer Center (MSK) helped develop a machine-learning tool to help find cancer cells that remain after surgery; led to Food and Drug Administration approval for CAR T cell therapy against mantle cell lymphoma; tested a liquid biopsy approach
-
News
A surprising finding challenges long-held dogma about how certain immune cells develop into specialized types in diverse tissues.
… Thursday, September 8, 2016 Summary Macrophages are immune cells that exist in diverse forms in various tissues. They interact constantly with cancer cells and appear to both target them and assist them under different circumstances. A new finding sheds light on how macrophages develop into different
-
2024 Annual Report
Learn about MSK's expertise and compassion in caring for people under 50 who are facing cancer.
… Friday, June 6, 2025 When 26-year-old Jo Luzarraga was diagnosed with breast cancer in Manila, Philippines, her older sister Jan Claire swung into action. “I told her, you’re moving to Queens, New York, to live with me and my daughter and my partner,” says Jan Claire, who is 40. “And you’re going to
-
News
Today Memorial Sloan Kettering (MSK) announced the appointment of a task force that will assess MSK policies and processes for reporting and managing outside activities and industry-supported clinical trials.
… Friday, September 21, 2018 Today Memorial Sloan Kettering (MSK) announced the appointment of a task force that will assess MSK policies and processes for reporting and managing outside activities and industry-supported clinical trials. The task force was announced in a statement from MSK President and
-
2023 Annual Report
Learn how experimental vaccine might train the immune system to prevent pancreatic cancer from returning.
… Monday, June 10, 2024 Pancreatic cancer has long been a forbidding disease. While the five-year survival rate has inched upward in recent years, it remains quite low — about 12%. But surgeon-scientist Vinod Balachandran, MD , has focused on a glimmer of hope: A small percentage of people manage to beat
-
News
Discover what Memorial Sloan Kettering contributed to the science and medicine of x-rays.
… Tuesday, October 4, 2016 Summary Since 1902, Memorial Sloan Kettering has been a pioneer in the science and medicine of x-rays, developing many of the radiation techniques in use today. In a previous post , we recounted the history of radium therapy at Memorial Sloan Kettering. Radium, a naturally occurring
-
News
Investigators at Memorial Sloan Kettering Cancer Center, along with collaborating teams at the Cleveland Clinic and the University of Michigan, have completed the first large-scale, multi-institutional study of prostate cancer death after standard treatment to remove the prostate since PSA screening has become widely used as a method to screen for the disease.
… Monday, July 27, 2009 Investigators at Memorial Sloan Kettering Cancer Center (MSKCC), along with collaborating teams at the Cleveland Clinic and the University of Michigan, have completed the first large- scale, multi-institutional study of prostate cancer death after standard treatment to remove the
-
News
Learn about insights that could lead to a new class of drugs against cancers caused by RAS gene mutations.
… Wednesday, October 30, 2024 Each year, more than 3 million people are diagnosed with cancers driven by mutations in three RAS-family genes: KRAS, NRAS , and HRAS . RAS-family mutations are associated with numerous types of cancer. KRAS mutations are found in pancreatic cancer , colorectal cancer ,
-
News
Clues emerge about why promising new breast cancer drugs sometimes don’t work — and what might be done about it.
… Monday, December 10, 2018 Summary A new class of drugs called CDK4/6 inhibitors has been effective in women with breast cancer . However, some people don’t respond to the drugs, or they develop resistance over time. A study by MSK researchers has identified two genes linked to this resistance. The most